Munich Cancer Registry

ICD-10 C83.7: Burkitt lymphoma

Survival

Year of diagnosis	1988-1997	1998-2020
Patients	38	197
Diseases	38	197
Cases evaluated	37	180
Creation date	04/15/2022	
Database export	12/20/2021	
Population	4.92 m	

BERLIN

GERMANY

BAVARIA

MUNICH

Munich Cancer Registry
Cancer Registry Bavaria - Upper Bavaria Regional Center
at Klinikum Grosshadern/IBE
Marchioninistr. 15
Munich, 81377
Germany

https://www.tumorregister-muenchen.de/en

https://www.tumorregister-muenchen.de/en/facts/surv/sC837_E-ICD-10-C83.7-Burkitt-lymphoma-survival.pdf

Index of figures and tables

ICD-10 C83.7: Burkitt lymphoma
Period of diagnosis
*Relative survival 1988-2020*

Figure 1a. Relative survival of patients with Burkitt lymphoma by period of diagnosis. Included in the evaluation are 215 cases diagnosed between 1988 and 2020.

The survival results of the SEER program (Surveillance, Epidemiology, and End Results) of the American National Cancer Institute (NCI) are summarized as the period of diagnosis from 2000 to 2018, and are represented by colored diamonds in order to facilitate comparisons between MCR and SEER.

The presented survival curves are derived from clinical records with valid follow-up informations, which means that death certificate cases (DCO) cases are omitted from the analysis. With this one restriction, the MCR has provided population-based statistics since 1998, collecting data on all cancer cases in the region of southern Bavaria. Historical data of previous time periods can be heavily selected, therefore, univariate survival comparisons of the presented time periods must be carefully considered. Nonetheless, all calculable survival curves are depicted to facilitate the comparison of long time follow-up analyses of relative survival between particular cancers.

	Period of diagnosis					
	1988-1997 n=37		1998-2006 n=58		2007+ n=120	
Years	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0	100.0	100.0
1	74.3	74.2	68.1	68.5	75.3	75.8
2	65.5	66.4	66.3	66.4	69.1	70.6
3	65.5	65.3	62.6	64.3	67.2	69.2
4	62.5	63.4	58.9	60.1	67.2	69.0
5			55.3	57.7	63.8	66.9
6			55.3	57.2	63.8	66.3
7			55.3	56.6	61.4	64.9
8			53.3	56.7	61.4	64.7
9			53.3	56.7	61.4	64.6
10			53.3	56.8	59.7	64.1
11			53.3	56.9	59.7	63.1
12			53.3	57.0	59.7	62.2
13			53.3	57.0		
14			51.2	57.0		
15			51.2	56.8		
Median			17.2			

Table 1b. Observed (obs.) and relative (rel.) survival of patients with Burkitt lymphoma by period of diagnosis for period 1988-2020 (N=215).

ICD-10 C83.7: Burkitt lymphoma
Sex
Survival 1998-2020

Figure 2a. Survival of patients with Burkitt lymphoma by sex. Included in the evaluation are 178 cases diagnosed between 1998 and 2020.

	Sex			
	Male n=122		Female n=56	
Years	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0
1	78.2	78.6	61.4	61.7
2	73.0	74.5	57.6	57.8
3	71.2	73.1	53.6	55.4
4	70.2	72.2	51.6	52.6
5	67.1	70.2	47.5	49.7
6	67.1	69.9	47.5	47.7
7	66.0	69.1		
8	64.9	69.2		
9	64.9	69.3		
10	64.9	69.5		
11	64.9	69.6		
12	64.9	69.7		
13	63.1	68.8		
14	60.5	67.7		
15	60.5	67.3		
Median			4.1	

Table 2b. Observed (obs.) and relative (rel.) survival of patients with Burkitt lymphoma by sex for period 1998-2020 (N=178).

Figure 2c. Conditional relative 2 / 5-year survival of patients with Burkitt lymphoma by sex. For 178 of 178 cases diagnosed between 1998 and 2020 valid data could be obtained for this item.

		Sex				
		Male			Female	
		Cond. surv. %			Cond. surv. %	
Years	n	2 yrs	5 yrs	n	2 yrs	5 yrs
0	122	74.5	70.2	56	57.8	49.7
1	92	92.2	88.1	32	88.7	76.5
2	80	96.6	92.6	30	89.1	
3	76	95.8	94.5	27	89.4	
4	69	95.9	95.3	26	88.5	
5	63	98.3	98.9			
6	61	97.7	98.4			
7	59	98.8	99.5			
8	54	100.3	99.3			
9	50	100.0	97.1			
10	47	99.4	96.0			

Table 2d. Conditional relative 2 / 5-year survival of patients with Burkitt lymphoma by sex for period 1998-2020 (N=178).

Conditional relative survival rates refer to the relative survival probability, in this case for 2 and 5 years after cancer diagnosis, compared to the age- and sex-matched population (=100 %) under the condition of being alive for a certain time period (x-axis in Figure 2a). The results illustrate to what extent the cancer induced mortality of particular subgroups declines in the subsequent years after detection of the malignancy. For instance, according to the presented survival statistics, patients in the subgroup sex="Male", who are alive at least 3 years after cancer diagnosis, the conditional relative 2-year survival rate is 95.8% (n=76).

ICD-10 C83.7: Burkitt lymphoma
Age category
Observed survival 1998-2020

Figure 3a. Observed survival of patients with Burkitt lymphoma by age category. Included in the evaluation are 178 cases diagnosed between 1998 and 2020.

ICD-10 C83.7: Burkitt lymphoma
Age category
*Relative survival 1998-2020*

Figure 3b. Relative survival of patients with Burkitt lymphoma by age category. Included in the evaluation are 178 cases diagnosed between 1998 and 2020.

	0-19 yrs n=32		20-39 yrs n=38		40-59 yrs n=44		60+ yrs n=64	
Years	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
1	96.6	93.2	86.8	86.0	72.4	72.6	54.1	55.6
2					72.4	71.2	45.9	48.4
3					67.0	67.0	42.4	46.6
4					64.0	65.0	40.6	44.5
Median							1.1	

Table 3c. Observed (obs.) and relative (rel.) survival of patients with Burkitt lymphoma by age category for period 1998-2020 (N=178).

ICD-10 C83.7: Burkitt lymphoma
Ann Arbor staging
*Relative survival 1998-2020*

Figure 4a. Relative survival of patients with Burkitt lymphoma by Ann Arbor staging. For 86 of 178 cases diagnosed between 1998 and 2020 valid data could be obtained for this item. The grey line represents the subgroup of 92 patients with missing values regarding Ann Arbor staging (51.7 % of 178 patients, the percent values of all other categories are related to n=86). Subgroups with sample size <20 are omitted from the chart.

	Ann Arbor staging			
	IV		NA	
	n=46		n=92	
Years	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0
1	61.7	62.2	67.6	67.9
2	61.7	61.7	60.8	62.3
3	61.7	61.1	56.1	58.2
4	59.1	58.5	54.8	56.7
5			50.9	53.6
6			50.9	52.7
7			49.6	51.5
8			48.3	51.3
9			48.3	51.1
10			48.3	50.8
11			48.3	50.6
12			48.3	50.4
Median			6.0	

Table 4b. Observed (obs.) and relative (rel.) survival of patients with Burkitt lymphoma by Ann Arbor staging for period 1998-2020 (N=86).

ICD-10 C83.7: Burkitt lymphoma
Progressionsform
*Time to first progression (TTP) 1998-2020*

Figure 5a. Time to first progression of 177 patients with Burkitt lymphoma diagnosed between 1998 and 2020 (in solid cancers M0 only) estimated by cumulative incidence function (CI, solid line) accounting for death as competing risk and by inverse Kaplan-Meier estimate (1-KM, dashed line). The frequency of events may be underestimated due to underreporting.

	Type of progression	
	Any type (CI)	Any type (1-KM)
N	177	177
Events	84	84
compet.	11	
Years	%	%
0	0.0	0.0
1	36.6	37.6
2	40.7	41.9
3	42.6	43.9
4	43.2	44.5
5	47.2	49.0
6	47.2	49.0
7	48.7	50.6
8	48.7	50.6
9	49.5	51.5
10	49.5	51.5

Table 5b. Time to first progression of patients with Burkitt lymphoma for period 1998-2020 (N=177), also showing the total of progression events (Events) and of deaths as competing risk (compet.).

Shortcuts

MCR	Munich Cancer Registry, Germany	
NCI	National Cancer Institute, USA	
SEER	Surveillance, Epidemiology, and End Results, USA	
UICC	Union for International Cancer Control, Geneva	
DCO	Death certificate only	Death certificate provides the only notification to the registry.
NA	Not available	
NOS	Not otherwise specified	
OS	Overall/Observed survival	Overall/Observed survival (Kaplan-Meier estimate) Date of entry: diagnosis Event: death from any cause
RS	Relative survival	Survival compared to "general population", ratio of observed to expected survival (Ederer II method), reflecting cancer specific survival
AS	Assembled survival	Assembled chart of observed, expected, relative survival
CS	Conditional survival	Survival probability under the condition of surviving a given period of time
TTP	Time to progression	Time to first progression / relapse Date of entry: diagnosis Event: (progression / relapse): first local-, lymph node recurrence, distant metastasis or unspecified progression
	1-KM	1 minus Kaplan-Meier estimator ("inverse" Kaplan-Meier estimator)
	CI	Cumulative incidence Death as competing risk (according to Kalbfleisch und Prentice)
PPS	Post-progression survival	Survival since first progression / relapse (Kaplan-Meier estimate) Date of entry (progression / relapse): first local-, lymph node recurrence, distant metastasis or unspecified progression Event: death from any cause

Recommended Citation

Munich Cancer Registry. Survival ICD-10 C83.7: Burkitt lymphoma [Internet]. 2022 [updated 2022 Apr 15; cited 2022 Jun 1]. Available from: https://www.tumorregister-muenchen.de/en/facts/surv/sC837_E-ICD-10-C83.7-Burkitt-lymphoma-survival.pdf

Copyright

The content of the public web site provided by the Munich Cancer Registry is available worldwide and free of charge. All documents are free to download, utilize, copy, print-out and distribute, providing that the MCR is referenced.

Disclaimer

The Munich Cancer Registry reserves the right to not be responsible for the topicality, correctness, completeness or quality of the information provided. Liability claims regarding damage caused by the use of any information provided, including any kind of information which is incomplete or incorrect, will therefore be rejected.